Chemical formula: C₇H₁₁NO₇P₂ Molecular mass: 283.112 g/mol PubChem compound: 5245
Risedronic acid is indicated for:
Population group: only adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: women, only adults (18 years old or older)
Treatment of postmenopausal osteoporosis, to reduce the risk of vertebral fractures.
Treatment of established postmenopausal osteoporosis, to reduce the risk of hip fractures.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: men, only adults (18 years old or older)
Treatment of osteoporosis in men at high risk of fractures.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: women, only adults (18 years old or older)
Prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: women, only adults (18 years old or older)
To maintain or increase bone mass in postmenopausal women undergoing long-term (more than 3 months), systemic corticosteroid treatment at doses ≥7.5mg/day prednisone or equivalent.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Risedronic acid is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
